Add to ORKGObjective: To ascertain clinical outcome following cyclical intravenous pamidronate therapy in a group of infants and young children with type III osteogenesis imperfecta (OI). Design, setting and method: A prospective observational study was carried out on infants and young children referred to Ward 9 Lady Ridgeway Hospital (LRH) for assessment and treatment of O
Severe osteogenesis imperfecta (OI) is a hereditary disorder char-acterized by increased bone fragil...
Cyclical neridronate treatment, started just after diagnosis at birth, had positive effects on growt...
Objectives: To conduct a systematic review of epidemiological literature to determine the incidence ...
Aim: To find an effective symptomatic treatment for osteogenesis imperfecta (OI). Methods: In a pros...
Introduction: Osteogenesis imperfecta (OI) is a group of genetic disorders with collagen bone defec...
Objective: Evaluate clinical outcome of early cyclic intravenous pamidronate treatment in children w...
Objective To evaluate prospectively the efficacy of bisphosphonate treatment in infants with severe ...
Osteogenesis imperfecta is a genetic disorder of extracellular matrix, characterized with decreased ...
Background/Aims: Intravenous bisphosphonate therapy is the first-line treatment in moderate-to-sever...
Abstract Osteogenesis imperfecta is a hereditary disorder of connective tissues characterised by low...
Background: Osteogenesis imperfecta (OI) is a group of genetic diseases with a wide spectrum of seve...
WOS: 000238794300006PubMed ID: 16848111Different therapy models have been tried in order to decrease...
The article presents a case of surgical extraction of impacted third molars in a 17 y. o. boy with o...
Intravenous neridronate infusions, administered quarterly, significantly increase BMD and lower the ...
Osteogenesis imperfecta is a heritable condition characterized by abnormally brittle bones, with an ...
Severe osteogenesis imperfecta (OI) is a hereditary disorder char-acterized by increased bone fragil...
Cyclical neridronate treatment, started just after diagnosis at birth, had positive effects on growt...
Objectives: To conduct a systematic review of epidemiological literature to determine the incidence ...
Aim: To find an effective symptomatic treatment for osteogenesis imperfecta (OI). Methods: In a pros...
Introduction: Osteogenesis imperfecta (OI) is a group of genetic disorders with collagen bone defec...
Objective: Evaluate clinical outcome of early cyclic intravenous pamidronate treatment in children w...
Objective To evaluate prospectively the efficacy of bisphosphonate treatment in infants with severe ...
Osteogenesis imperfecta is a genetic disorder of extracellular matrix, characterized with decreased ...
Background/Aims: Intravenous bisphosphonate therapy is the first-line treatment in moderate-to-sever...
Abstract Osteogenesis imperfecta is a hereditary disorder of connective tissues characterised by low...
Background: Osteogenesis imperfecta (OI) is a group of genetic diseases with a wide spectrum of seve...
WOS: 000238794300006PubMed ID: 16848111Different therapy models have been tried in order to decrease...
The article presents a case of surgical extraction of impacted third molars in a 17 y. o. boy with o...
Intravenous neridronate infusions, administered quarterly, significantly increase BMD and lower the ...
Osteogenesis imperfecta is a heritable condition characterized by abnormally brittle bones, with an ...
Severe osteogenesis imperfecta (OI) is a hereditary disorder char-acterized by increased bone fragil...
Cyclical neridronate treatment, started just after diagnosis at birth, had positive effects on growt...
Objectives: To conduct a systematic review of epidemiological literature to determine the incidence ...